AXIM · Axim Biotechnologies, Inc. · Debt
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.”View the 10-Q filed Aug 19, 2024
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Capital lease obligations | 2024-06-30 | USD 186,492 | 10-Q filed 2024-08-19 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Current long-term debt and lease obligations | 2024-06-30 | USD 92,645 | 10-Q filed 2024-08-19 |
| Long-term debt, including current maturities | 2024-06-30 | USD 5,965,990 | 10-Q filed 2024-08-19 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent long-term debt and lease obligations | 2024-06-30 | USD 93,847 | 10-Q filed 2024-08-19 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.